


PF-03049423 free base

Cat. No.:	HY-10679
CAS No.:	954138-07-9
Molecular Formula:	C ₂₄ H ₃₂ N ₆ O ₄
Molecular Weight:	468.55
Target:	Phosphodiesterase (PDE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PF-03049423 (Compound PF-5) free base is a potent and highly selective phosphodiesterase-5A inhibitor with an IC ₅₀ of about 0.2 nM for rat and human platelet enzyme. PF-03049423 free base can be used for the research of acute ischaemic stroke ^[1] .									
IC₅₀ & Target	PDE5A	rat and human platelet enzyme ~0.2 nM (IC ₅₀)								
In Vivo	<p>PF-03049423 (Compound PF-5) (1-10 mg/kg; s.c.; b.i.d. for 7 days) promotes functional recovery in a rat model of severe stroke induced by permanent middle cerebral artery occlusion^[1].</p> <p>PF-03049423 (1.0 mg/kg b.i.d. or 0.6 mg/kg q.d. for 7 days) improves poststroke sensory-motor behavioral outcome even when the treatment is initiated 24-72 hours after occlusion^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) mode^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.1, 1, or 10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection, b.i.d. for 7 days</td> </tr> <tr> <td>Result:</td> <td>Improved functional recovery at 1 mg/kg and 10 mg/kg.</td> </tr> </table>		Animal Model:	Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) mode ^[1]	Dosage:	0.1, 1, or 10 mg/kg	Administration:	Subcutaneous injection, b.i.d. for 7 days	Result:	Improved functional recovery at 1 mg/kg and 10 mg/kg.
Animal Model:	Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) mode ^[1]									
Dosage:	0.1, 1, or 10 mg/kg									
Administration:	Subcutaneous injection, b.i.d. for 7 days									
Result:	Improved functional recovery at 1 mg/kg and 10 mg/kg.									

REFERENCES

[1]. Menniti FS, et al. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. *J Pharmacol Exp Ther.* 2009 Dec;331(3):842-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA